CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia

This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-65 years) with Severe Hypertriglyceridemia(sHTG).

NCT Number	NCT07657780
Lead Sponsor	CorrectSequence Therapeutics Co., Ltd Collaborators: The First Affiliated Hospital of Anhui Medical University
Conditions	Severe Hypertriglyceridemia (sHTG)
Enrollment	15 participants
Start Date	2026-06-15
Primary Completion	2028-03-15 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-18